August 15, 2017 07:30 AM EDTUpdated 12:11 PM
Bioregnum
Opinion

Trump's re­newed broad­sides on drug pric­ing did­n't even dent bio­phar­ma this time

Late Mon­day Pres­i­dent Don­ald Trump took his sec­ond shot at Mer­ck CEO Ken Fra­zier. Clear­ly still ran­kled by Fra­zier’s de­ci­sion to re­sign from Trump’ …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

For­bion rais­es €2.1B for two new biotech funds af­ter se­ries of com­pa­ny ex­its

Ex­clu­sive: Biotech tools com­pa­ny rais­es $75M for pro­tein man­u­fac­tur­ing tech 

Mary­land biotech gets green light for stem cell-de­rived ther­a­py for di­a­betes, aim­ing to com­pete with Ver­tex

Tol­er­ance Bio emerges from stealth with $17.2M to ad­vance ther­a­pies de­vel­oped from the thy­mus

Eli Lil­ly re­veals £279M in­vest­ment in the UK through new gov­ern­ment deal

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times